CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) ("Takeda") today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation. TOURMALINE-MM4 is the first industry sponsored Phase 3 trial to explore the concept of switch maintenance, the use of medicines not included in initial induction therapy, in this setting. NINLARO is currently not approved for this specific use.
We are very encouraged by the results of the TOURMALINE-MM4 trial and continue our forward momentum in developing maintenance options for multiple myeloma patients. Importantly, this is the third positive Phase 3 readout from the TOURMALINE clinical trial program, said Phil Rowlands, Ph.D., Head, Oncology Therapeutic Area Unit, Takeda. We remain committed to bringing this convenient and well-tolerated treatment option to patients.
The safety profile of NINLARO in the maintenance setting was consistent with previously reported results of single-agent NINLARO use, and there were no new safety signals identified in TOURMALINE-MM4.
Full data results will be submitted for presentation at an upcoming medical meeting.
About the TOURMALINE-MM4 Trial
TOURMALINE-MM4 is a randomized, placebo-controlled, double-blind Phase 3 study of 706 patients, designed to determine the effect of single-agent oral NINLAROTM (ixazomib) maintenance therapy on progression-free survival (PFS), compared to placebo, in adult patients newly diagnosed with multiple myeloma not treated with stem cell transplantation, who have completed 6-12 months of initial therapy and achieved a partial response or better. For additional information, please visit https://clinicaltrials.gov/ct2/show/NCT02312258.
About Multiple Myeloma
Multiple myeloma is a life-threatening rare blood cancer that arises from the plasma cells, a type of white blood cell that is made in the bone marrow. These plasma cells become abnormal, multiply and release a type of antibody known as a paraprotein, which causes symptoms of the disease, including bone pain, frequent or recurring infections and fatigue, a symptom of anemia. These malignant plasma cells have the potential to affect many bones in the body and can cause a number of serious health problems affecting the bones, immune system, kidneys and red blood cell count. The typical multiple myeloma disease course includes periods of symptomatic myeloma followed by periods of remission. Nearly 230,000 people around the world live with multiple myeloma, with approximately 114,000 new cases diagnosed globally each year.
About NINLAROTM (ixazomib) capsules
NINLARO (ixazomib) is an oral proteasome inhibitor which is being studied across the continuum of multiple myeloma treatment settings. NINLARO was first approved by the U.S. Food and Drug Administration (FDA) in November 2015 and is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is currently approved in more than 60 countries, including the United States, Japan and in the European Union, with more than 10 regulatory filings currently under review. It was the first oral proteasome inhibitor to enter Phase 3 clinical trials and to receive approval.
The comprehensive ixazomib clinical development program, TOURMALINE, includes several ongoing pivotal trials, which together are investigating major multiple myeloma patient populations:
In addition to the TOURMALINE program, ixazomib is being evaluated in multiple therapeutic combinations for various patient populations in investigator initiated studies globally.
NINLAROTM (ixazomib) capsules: Global Important Safety Information
SPECIAL WARNINGS AND PRECAUTIONSThrombocytopenia has been reported with NINLARO (28% vs. 14% in the NINLARO and placebo regimens, respectively) with platelet nadirs typically occurring between Days 14-21 of each 28-day cycle and recovery to baseline by the start of the next cycle. It did not result in an increase in hemorrhagic events or platelet transfusions. Monitor platelet counts at least monthly during treatment with NINLARO and consider more frequent monitoring during the first three cycles. Manage with dose modifications and platelet transfusions as per standard medical guidelines.
Gastrointestinal toxicities have been reported in the NINLARO and placebo regimens respectively, such as diarrhea (42% vs. 36%), constipation (34% vs. 25%), nausea (26% vs. 21%), and vomiting (22% vs. 11%), occasionally requiring use of antiemetic and anti-diarrheal medications, and supportive care.
Peripheral neuropathy was reported with NINLARO (28% vs. 21% in the NINLARO and placebo regimens, respectively). The most commonly reported reaction was peripheral sensory neuropathy (19% and 14% in the NINLARO and placebo regimens, respectively). Peripheral motor neuropathy was not commonly reported in either regimen (< 1%). Monitor patients for symptoms of peripheral neuropathy and adjust dosing as needed.
Peripheral edema was reported with NINLARO (25% vs. 18% in the NINLARO and placebo regimens, respectively). Evaluate patients for underlying causes and provide supportive care, as necessary. Adjust the dose of dexamethasone per its prescribing information or the dose of NINLARO for severe symptoms.
Cutaneous reactions occurred in 19% of patients in the NINLARO regimen compared to 11% of patients in the placebo regimen. The most common type of rash reported in both regimens was maculo-papular and macular rash. Manage rash with supportive care, dose modification or discontinuation.
Hepatotoxicity, drug-induced liver injury, hepatocellular injury, hepatic steatosis, and hepatitis cholestatic have been uncommonly reported with NINLARO. Monitor hepatic enzymes regularly and adjust dose for Grade 3 or 4 symptoms.
Pregnancy- NINLARO can cause fetal harm. Advise male and female patients of reproductive potential to use contraceptive measures during treatment and for an additional 90 days after the final dose of NINLARO. Women of childbearing potential should avoid becoming pregnant while taking NINLARO due to potential hazard to the fetus. Women using hormonal contraceptives should use an additional barrier method of contraception.
Lactation- It is not known whether NINLARO or its metabolites are excreted in human milk. There could be potential adverse events in nursing infants and therefore breastfeeding should be discontinued.
SPECIAL PATIENT POPULATIONSHepatic Impairment: Reduce the NINLARO starting dose to 3 mg in patients with moderate or severe hepatic impairment.
Renal Impairment: Reduce the NINLARO starting dose to 3 mg in patients with severe renal impairment or end-stage renal disease (ESRD) requiring dialysis. NINLARO is not dialyzable and, therefore, can be administered without regard to the timing of dialysis.
DRUG INTERACTIONSCo-administration of strong CYP3A inducers with NINLARO is not recommended.
ADVERSE REACTIONSThe most frequently reported adverse reactions ( 20%) in the NINLARO regimen, and greater than in the placebo regimen, were diarrhea (42% vs. 36%), constipation (34% vs. 25%), thrombocytopenia (28% vs. 14%), peripheral neuropathy (28% vs. 21%), nausea (26% vs. 21%), peripheral edema (25% vs. 18%), vomiting (22% vs. 11%), and back pain (21% vs. 16%). Serious adverse reactions reported in 2% of patients included thrombocytopenia (2%) and diarrhea (2%). For each adverse reaction, one or more of the three drugs was discontinued in 1% of patients in the NINLARO regimen.
For European Union Summary of Product Characteristics: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003844/WC500217620.pdf For US Prescribing Information: https://www.ninlarohcp.com/pdf/prescribing-information.pdf For Canada Product Monograph: http://www.takedacanada.com/ninlaropm
About Takeda Pharmaceutical Company LimitedTakeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
Important NoticeFor the purposes of this notice, press release means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (Takeda) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, Takeda is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words we, us and our are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
Forward-Looking StatementsThis press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takedas future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as targets, plans, believes, hopes, continues, expects, aims, intends, ensures, will, may, should, would, could anticipates, estimates, projects or similar expressions or the negative thereof. Forward-looking statements in this document are based on Takedas estimates and assumptions only as of the date hereof. Such forward-looking statements do not represent any guarantee by Takeda or its management of future performance and involve known and unknown risks, uncertainties and other factors, including but not limited to: the economic circumstances surrounding Takedas global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the timing and impact of post-merger integration efforts with acquired companies; and the ability to divest assets that are not core to Takedas operations and the timing of any such divestment(s), any of which may cause Takedas actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements. For more information on these and other factors which may affect Takedas results, performance, achievements, or financial position, see Item 3. Key InformationD. Risk Factors in Takedas most recent Annual Report on Form 20-F and Takedas other reports filed with the U.S. Securities and Exchange Commission, available on Takedas website at: https://www.takeda.com/investors/reports/sec-filings/ or at http://www.sec.gov. Future results, performance, achievements or financial position of Takeda could differ materially from those expressed in or implied by the forward-looking statements. Persons receiving this press release should not rely unduly on any forward-looking statements. Takeda undertakes no obligation to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results of Takeda in this press release may not be indicative of, and are not an estimate, forecast or projection of Takedas future results.
Read this article:
Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell...
- Brenner and Rector's The Kidney, 2-Volume Set. Edition No. 11 - ResearchAndMarkets.com - Associated Press - December 6th, 2019
- Stem Cells Market to a Revenue Opportunity of US$270.5 bn During the Period from 2025 - News Description - December 6th, 2019
- Stem cell Therapy Market 2019-2027| Business Scope and Investment Analysis By MEDIPOST, PHARMICELL Co., Ltd, Holostem Terapie Avanzate Srl, Mesoblast... - December 6th, 2019
- Cutting Through the Headlines: Are Scientists Really Growing Sentient "Mini-brains"? - Technology Networks - December 6th, 2019
- Year in Review: Respiratory Infection - MedPage Today - December 6th, 2019
- Whats Happening: IDF Shabbat of Heroes, Sephardic Papers - Jewish Journal - December 5th, 2019
- Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Breaking News Updates - December 5th, 2019
- Marine Coatings Market is Anticipated to Register a Value of XX Million by the end of 2017 - 2025 - Markets Gazette 24 - December 5th, 2019
- Stem Cell Market 2019 | What Will Be the Market Size and the Growth Rate Analysis by 2026? - Hitz Dairies - December 3rd, 2019
- Stem Cells Market is Expected to Register a Healthy CAGR of 13.8% During the Period from 2017 to 2025 - Statsflash - December 3rd, 2019
- BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND - BioSpace - November 28th, 2019
- Inside the Beltway: Abortion, immigration among forbidden topics at Thanksgiving table - Washington Times - November 28th, 2019
- Canine Stem Cell Therapy Market Value Projected to Expand by 2026 - The Hilltop Monitor - November 28th, 2019
- Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Industry News Info - November 28th, 2019
- Stem Cell Banking Market Size, Share, Growth, Future Prospects, Competitive Analysis and Forecast To 2026 - Med News Ledger - November 28th, 2019
- Lulu and Nana are the result of a defiant experiment in human gene modification - The Irish Times - November 28th, 2019
- Types of Adult Stem Cells - Stem Cell Institute - November 26th, 2019
- Adult Leukemia: What You Need to Know - Dana-Farber Cancer Institute - November 26th, 2019
- Hatching disease in a dish: The new frontier in drug testing - Maclean's - November 26th, 2019
- Bedfordshire Police officer reunited with woman whose life he saved through stem cell donation - Bedford Today - November 26th, 2019
- BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND - GlobeNewswire - November 26th, 2019
- Bedfordshire Police officer reunited with stem cell recipient - Cranfield and Marston Vale Chronicle - November 26th, 2019
- Keeping cells alive | Interviews - The Naked Scientists - November 26th, 2019
- Dana-Farber joins with leading Boston teaching hospitals and universities - Mirage News - November 26th, 2019
- Applying AI and CRISPR to stem cells to improve regenerative medicine - FierceBiotech - November 20th, 2019
- Decoding the building blocks of life: bit bio races toward a sustainable source of human cells - Proactive Investors UK - November 20th, 2019
- 1st SCD Trial Patient Shows CTX001 Gene Editing to be Safe, Effective - Sickle Cell Anemia News - November 20th, 2019
- CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib - BioSpace - November 20th, 2019
- Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology - Arizona Daily Star - November 20th, 2019
- Maltese abroad: the best-selling author with roots in Gozo - Times of Malta - November 20th, 2019
- Early Results Are Positive for Experimental CRISPR Therapies - The Scientist - November 19th, 2019
- CHMP recommends EMA approval of polatuzumab vedotin for the treatment of adult patients with R/R DLBCL - Lymphoma Hub - November 19th, 2019
- CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib - PRNewswire - November 19th, 2019
- Redding woman donates bone marrow, saves life of a father - FOX61 Hartford - November 16th, 2019
- Maxim Group Maintains Their Buy Rating on Brainstorm Cell Therapeutics (BCLI) - Smarter Analyst - November 16th, 2019
- How 3D Printing Is Turning Each And Every Industry On Its Head - SafeHaven.com - November 16th, 2019
- BIORESTORATIVE THERAPIES, INC. (OTCMKTS:BRTX) Files An 8-K Submission of Matters to a Vote of Security Holders - Market Exclusive - November 16th, 2019
- Global Cell Expansion Market 2019 is predicted to reach an excellent valuation of by 2024 - Galus Australis - November 16th, 2019
- Stem Cell Assay Market is Growing Massively in Upcoming Year with Top Key Players like GE Healthcare, Thermo Fisher Scientific Inc., Merck KGaA, Cell... - November 15th, 2019
- Bone marrow transplant: What it is, uses, risks, and recovery - Medical News Today - November 15th, 2019
- The Demand of Mesenchymal Stem Cells Market Research Report 2019 Future Growth, Demand, Application, Trends, Vendor Landscape, Industry Insight,... - November 15th, 2019
- BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Society - Yahoo Finance - November 14th, 2019
- BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update - GlobeNewswire - November 14th, 2019
- BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting - Yahoo Finance - November 14th, 2019
- INDIA Indian doctor: Medical innovation should not try to replace the Creator - AsiaNews - November 14th, 2019
- iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting - Send2Press Newswire - November 14th, 2019
- Contrasting BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - DFS Caller - November 14th, 2019
- Army veteran to save woman with blood cancer through stem cell donation - Stoke-on-Trent Live - November 12th, 2019
- Financial Contrast: BioRestorative Therapies (OTCMKTS:BRTX) and Livongo Health (OTCMKTS:LVGO) - DFS Caller - November 12th, 2019
- Autolus Therapeutics Plc (AUTL) Q3 2019 Earnings Call Transcript - The Motley Fool - November 9th, 2019
- Stem Cell Therapy Market Trends, Secondary Research With Geron Corporation, Vericel Corporation, Pluristem Therapeutics, Cytori Therapeutics, Fate... - October 29th, 2019
- Huntington's Marked by Inflammation and Changes in Brain's Striatum Before Symptoms, Study Finds - Huntington's Disease News - October 29th, 2019
- In 2030, Our Protein Will Come From a Laband We'll All Be Better Off For It - Singularity Hub - October 28th, 2019
- NASA plans to cut cost of space exploration by commercializing low-earth orbit - Digital Trends - October 27th, 2019
- BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference - BioSpace - October 27th, 2019
- Artificial Early Mouse Embryos Created In The Lab Using Stems Cells Rather Than Sperm Or Eggs - IFLScience - October 21st, 2019
- Healthcare Terms Are Out of Touch, Says Mom Advocate - Medscape - October 21st, 2019
- A stop-motion movie of the whole brain, starring new neurons - Spectrum - October 21st, 2019
- Humans evolved to think faster by slowing down brain development - New Scientist News - October 21st, 2019
- Stem Cell Banking Market was valued at $1986 million in 2016 - Markets Gazette - October 19th, 2019
- Republicans demand answers about government experiments with animals and fetal tissue - Washington Examiner - October 17th, 2019
- The Other Side of Stem Cell Research - The Tablet Catholic Newspaper - October 17th, 2019
- Reviewing MediciNova Inc. (MNOV)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 17th, 2019
- SI-BONE Inc. (SIBN) and Cesca Therapeutics Inc. (NASDAQ:KOOL) Comparing side by side - MS Wkly - October 17th, 2019
- Inherited Learning? It Happens, but How Is Uncertain - Quanta Magazine - October 17th, 2019
- Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and Magenta Therapeutics Inc. (NASDAQ:MGTA) - MS Wkly - October 17th, 2019
- Stem Cells Market to Gain Huge Traction Owing to Arrival of New-Fangled Treatments for Long-Lasting Sicknesses Till 2025 | Million Insights - P&T... - October 7th, 2019
- New Tools in the Works to Probe Adult Human Neurogenesis - The Scientist - October 7th, 2019
- Follow the lead of Aston Villa players and become a blood stem cell donor - 7500 To Holte - October 7th, 2019
- Starving Cancer by Cutting Off Its Favorite Foods, Glucose and Glutamine - American Council on Science and Health - October 6th, 2019
- We're making tiny brains in the lab should we be worried for them? - CBC.ca - October 6th, 2019
- Female Scientist To Lead Advanced Cancer Research Project In Space - SheThePeople - October 6th, 2019
- Cancer cells to be tested in zero gravity on Chinese Space Station - E&T Magazine - October 4th, 2019
- Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at 27th Annual Meeting of the European Orthopaedic... - October 4th, 2019
- Global Stem Cell Therapy Market Report, 2019-2030 : Focus on Treatment Type, Cell Source, Indication and Competitive Landscape - Space Market Research - October 4th, 2019
- Genmab Announces U.S. FDA Approval of DARZALEX (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple... - September 27th, 2019
- The unexpected functional diversity of reactive astrocytes - Baylor College of Medicine News - September 27th, 2019
- Troy resident 'gets it done' with ground-breaking treatment - Troy Daily News - September 27th, 2019
- Stem Cell Assay Market Overview by Industry Chain Information, Upstream Raw Materials & Downstream Industry 2017 2025 - Herald Space - September 27th, 2019
- Stem cells regrow long bones - WNDU-TV - September 20th, 2019